

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Hadley et al.

Patent No.: 7,167,744

Issued: January 23, 2007

For: **METHODS FOR QUANTIFYING THE
MORPHOLOGY AND AMPLITUDE OF
CARDIAC ACTION POTENTIAL
ALTERNANS**

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.323**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which are listed on the enclosed form PTO/SB/44.

Some errors were found in the application as filed by applicant, others are believed to be due to mistake on the part of the USPTO. Accordingly, the applicant will pay \$100.00 by Electronic Funds Transfer covering the fee set forth in 37 CFR 1.20(a).

The error now sought to be corrected is an inadvertent typographical error the correction of which does not involve new matter or require reexamination.


Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0665, under Order No. 330498002US.

Dated: 3 Nov. 2008

Respectfully submitted,

By



Paul T. Parker

Registration No.: 38,264
PERKINS COIE LLP
P.O. Box 1247
Seattle, Washington 98111-1247
(206) 359-8000
(206) 359-9000 (Fax)
Attorney for Applicant

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,167,744

Page 1 of 2

APPLICATION NO.: 10/815,910

ISSUE DATE : January 23, 2007

INVENTOR(S) : Hadley et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 2, under "Other Publications", in column 1, line 29, delete "altemans" and insert -- alternans --, therefore.

On page 2, under "Other Publications", in column 2, line 13, delete "transiet" and insert -- transient --, therefore.

On page 2, under "Other Publications", in column 2, line 27, delete "Interleads" and insert -- Interlead --, therefore.

On page 2, under "Other Publications", in column 2, line 29, delete "2003.," and insert -- 2003. --, therefore.

On sheet 19 of 20, FIG. 15, line 1, delete "HR(BPM:)" and insert -- IIR(BPM) --, therefore.

In column 3, line 28, delete "determined" and insert -- determine --, therefore.

In column 8, line 12, delete "Q-Stresse®" and insert -- Q-Stress® --, therefore.

In column 10, line 16, after "trace" insert -- . --.

In column 11, line 56, delete "Nyquest" and insert -- Nyquist --, therefore.

In column 17, line 13, after "and" delete "I" and insert -- I --, therefore.

In column 17, line 22, delete "alterman-estimates." and insert -- alternan estimates. --, therefore.

In column 17, line 52, delete "P3(i)" and insert -- P₃(i) --, therefore.

In column 18, lines 27–39, delete "This permits easy visual assessment of amplitude in addition to convenient evaluation of the alterman signal signature. The complete test summary, for all leads, is developed by compositing together each individual alternan estimate as shown in FIG. 15. This is the most important summary graph that forms the basis for clinical analysis. It has been designed to clearly show the onset and amplitude of any statistically significant alternan signal and highlight alternan disassociation observed across the lead set, which should be visible as both changes in shape from lead to lead and changes in color (amplitude). Key elements of the display are:" and insert the same on Col. 18, Line 26, after "signal.", as a continuation of the same paragraph.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,167,744

Page 2 of 2

APPLICATION NO.: 10/815,910

ISSUE DATE : January 23, 2007

INVENTOR(S) : Hadley et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 19, line 12, delete "Alternans" and insert - - Alternans - -, therefore.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Perkins Coie LLP
P.O. Box 1247
Seattle, WA
98111-1247

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 10 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form call 1-800-PTO-9199 and select option 2

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.